Octagon Capital Advisors »

Palisade Bio shares owned by Octagon Capital Advisors

Quarter-by-quarter ownership of Palisade Bio (PALI) shares owned by Octagon Capital Advisors from 13F filings

Historical chart of Octagon Capital Advisors investment in Palisade Bio

Tip: Access up to 7 years of quarterly data

All positions including Palisade Bio held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Palisade Bio by Octagon Capital Advisors

Quarter filed Position value Share count Share price at filing
2025-12-31 $23M 9.6M 2.35

More positions owned by Octagon Capital Advisors

Abivax Sa Sponsored Ads (ABVX)
Dianthus Therapeutics (DNTH)
Cogent Biosciences (COGT)
Taysha Gene Therapies Com Shs (TSHA)
Gossamer Bio (GOSS)
Kymera Therapeutics (KYMR)
Arrivent Biopharma (AVBP)
Trevi Therapeutics (TRVI)
Ocular Therapeutix (OCUL)
Mind Medicine Mindmed Com New (MNMD)
Cg Oncology Call Option (CGON)
Alumis (ALMS)
Palisade Bio (PALI)
Cidara Therapeutics Com New (CDTX)
Bioage Labs (BIOA)

View all positions for Octagon Capital Advisors

Top funds holding Palisade Bio

Commodore Capital
Point72 Asset Management
Octagon Capital Advisors
Eversept Partners
Franklin Resources
Renaissance Technologies
Vivo Capital
Vanguard Group
ADAR1 Capital Management
Geode Capital Management
Platinum Investment Mangement
Hudson Bay Capital Management
State Street Corporation
Goldman Sachs Group
Jane Street

View all funds holding Palisade Bio